| HOME >> MEDICINE >> TECHNOLOGY |
$ 20,048
$ 22,023COST OF GOODS SOLD2,716
3,127
10,284
10,418Gross profit
2,376
3,388
9,764
11,605OPERATING EXPENSES:Selling, general and administrative
3,309
2,397
10,933
10,319Research and development
354
714
2,305
3,182Restructuring charges
66
—
138
—3,729
3,111
13,376
13,501INCOME (LOSS) FROM OPERATIONS(1,353)
277
(3,612)
(1,896)OTHER INCOME:Interest income (expense)
(6)
1
(4)
15Other, net
632
7
632
3626
8
628
18INCOME (LOSS) BEFORE INCOME TAXES(727)
285
(2,984)
(1,878)INCOME TAX EXPENSE 40
156
150
42NET INCOME (LOSS)$
(767)
$ 129
$ (3,134)
$ (1,920)BASIC AND DILUTED INCOME (LOSS) PER SHARE:From continuing operations
$
(0.02)
$
.00
$ (0.06)
$ (0.04)BASIC WEIGHTED AVERAGE SHARES OUTSTANDING49,289,672
49,189,672
49,243,839
49,189,672DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING49,289,672
49,217,942
49,243,839
49,189,672Transgenomic, Inc.Summary Financial ResultsUnaudited Condensed Consolidated Statements of Cash Flows(dollars in thousands)Year Ended December 31,20102009NET CASH FLOWS PROVIDED BY (USED IN) OPERATING ACTIVITIES$ (1,718)
$
,267NET CASH FLOWS USED IN INVESTING ACTIVITIES(6,226)
(377)NET CASH FLOWS PROVIDED BY FINANCING ACTIVITIES5,761
—EFFECT OF FOREIGN CUR
'/>"/>
| SOURCE Transgenomic, Inc. Copyright©2010 PR Newswire. All rights reserved |